Epilepsy Diagnosis Articles & Analysis
3 news found
NeuroSigma, Inc., a bioelectronic medical device company, today announced FDA Breakthrough Device Designation for its Monarch eTNS System® for “adjunctive use for reducing the frequency of seizures in individuals 18 years of age or older diagnosed with epilepsy characterized by partial-onset seizures, with or without secondary generalization, that are refractory to two or more ...
The SPEAC System can be particularly useful to confirm the diagnosis in patients with infrequent events that are suspected to be generalized tonic clonic seizures. Having objective data to interpret an event can help obtain the right diagnosis and therapeutic choices.” The SPEAC System, which first received FDA De Novo clearance in February 2017, is ...
Zeto’s CEO Aswin Gunasekar was in business school at the University of Texas, Austin, when he took an interest in epilepsy diagnosis after watching a family member battle the condition. ...